The DOI matches its Crossref record; 210 of the 211 references it cites were found in a registry or an index.
The tubular hypothesis of nephron filtration and diabetic kidney disease
Open accessAbstract
Kidney size and glomerular filtration rate (GFR) often increase with the onset of diabetes, and elevated GFR is a risk factor for the development of diabetic kidney disease. Hyperfiltration mainly occurs in response to signals passed from the tubule to the glomerulus: high levels of glucose in the glomerular filtrate drive increased reabsorption of glucose and sodium by the sodium-glucose cotransporters SGLT2 and SGLT1 in the proximal tubule. Passive reabsorption of chloride and water also increases. The overall capacity for proximal reabsorption is augmented by growth of the proximal tubule, which (alongside sodium-glucose cotransport) further limits urinary glucose loss. Hyperreabsorption of sodium and chloride induces tubuloglomerular feedback from the macula densa to increase GFR. In addition, sodium-glucose cotransport by SGLT1 on macula densa cells triggers the production of nitric oxide, which also contributes to glomerular hyperfiltration. Although hyperfiltration restores sodium and chloride excretion it imposes added physical stress on the filtration barrier and increases the oxygen demand to drive reabsorption. Tubular growth is associated with the development of a senescence-like molecular signature that sets the stage for inflammation and fibrosis. SGLT2 inhibitors attenuate the proximal reabsorption of sodium and glucose, normalize tubuloglomerular feedback signals and mitigate hyperfiltration. This tubule-centred model of diabetic kidney physiology predicts the salutary effect of SGLT2 inhibitors on hard renal outcomes, as shown in large-scale clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a paracrine manner, adenosine constricts the afferent arteriole through the adenosine 1 receptor, thereby decreasing glomerular perfusion and hyperfiltration, a central mechanism for progressive glomerular injury (21,22).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
Miracle, C. M., Rieg, T., Mansoury, H., Vallon, V., & Thomson, S. C. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00491.2007 · Cited by 18
Self-citationThe Salt Paradox of the Early Diabetic Kidney Is Independent of Renal Innervation
Birk, C., Richter, K., Huang, D., Piesch, C., Luippold, G., & Vallon, V. (2003) · Kidney & Blood Pressure Research · doi:10.1159/000073941 · Cited by 17
Self-citationRelationship between kidney volume, microalbuminuria and duration of diabetes mellitus.
Bognetti, E., Zoja, A., Meschi, F., L., P. P., & Chiumello, G. (1996) · PubMed · Cited by 12
Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J. S., Bakris, G. L., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H., et al. (2019) · UCL Discovery (University College London) · Cited by 12
Blantz, R. C., Singh, P., Deng, A., Thomson, S. C., & Vallon, V. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00329.2011 · Cited by 11
Self-citationFlow‐dependent transport in a mathematical model of rat proximal tubule
Weinstein, A. M., Weinbaum, S., Duan, Y., Du, Z., Yan, Q., & Wang, T. (2007) · The FASEB Journal · doi:10.1096/fasebj.21.6.a827-d · Cited by 10
Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors
Vaduganathan, M., & Januzzi, J. L. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.008 · Cited by 10
Thomson, S. C. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00066.2018 · Cited by 7
Self-citationHuang, W., Patel, R., Ōnishi, A., Crespo‐Masip, M., Soleimani, M., Freeman, B., & Vallon, V. (2018) · The FASEB Journal · doi:10.1096/fasebj.2018.32.1_supplement.620.17 · Cited by 6
Self-citationvan Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Kramer, M. H. H., Nieuwdorp, M., Joles, J. A., & van Raalte, D. H. (2019) · Diabetes · doi:10.2337/db19-243-or · Cited by 4
Research works printed but not linked: 1
- Fu, Y., Gerasimova, M., Mayoux, E., Masuda, T. & Vallon, V. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration. Diabetes 63, (supplement 1), A132 (2014).
Cited by
Sorted by citations
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 724
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 627
Kopp, J. B., Anders, H., Suszták, K., Podestà, M. A., Remuzzi, G., Hildebrandt, F., & Romagnani, P. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0196-7 · Cited by 570
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 573
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 556
Self-citation
Metadata
- Authors
- Vallon, V., & Thomson, S. C.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Vallon, Volker
- Venue
- Nature Reviews Nephrology
- Published
- 2020-03-09
- Volume
- 16
- Issue
- 6
- Pages
- 317-336
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- PMC
- PMC7242158
- OpenAlex
- W3009930262
- Cited by
- 465
- References
- 211
- Citations by year
- 2026: 80 · 2025: 75 · 2024: 79 · 2023: 70 · 2022: 79 · 2021: 55 · 2020: 24
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Nephrology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (1rf1ag061296-01a1)
- National Institute on Aging (RF1-AG061296)
- National Heart, Lung, and Blood Institute (R01HL142814)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079337, R01DK106102, R01DK112042)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic nephropathy, glomerular hyperfiltration, tubuloglomerular feedback, SGLT2, SGLT1, proximal tubular reabsorption, macula densa, nitric oxide, renal fibrosis, SGLT2 inhibitors, glomerular filtration rate
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Chlorides, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fibrosis, Glomerular Filtration Rate, Glucose, Humans, Hypertrophy, Inflammation, Kidney Glomerulus, Kidney Tubules, Nephrons, Nitric Oxide, Sodium, Cellular Senescence, Sodium-Glucose Transporter 1, Sodium-Glucose Transporter 2, Glomerular Filtration Barrier, Renal Reabsorption
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
